Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk
Several cardiometabolic comorbidities are common in patients with narcolepsy. Often these disorders are overlooked, but they have important implications in the management of this condition. Some medications used to treat symptoms of narcolepsy may have potential negative effects on cardiovascular health, including in patients that are sensitive to sodium, such as those with hypertension, heart failure, or impaired renal function.
In this activity, multi-disciplinary experts will overview the link between cardiometabolic and cardiovascular risk and narcolepsy, individualization of therapy for narcolepsy patients with cardiovascular risk, as well as narcolepsy treatment options and recent advances in pharmacotherapy for these patients. The information is presented in an easy and digestible format, accompanied by additional resources and suggested readings.
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
After completing this activity, the participant should be better able to:
- Recognize that cardiometabolic risk factors are common in patients with narcolepsy
- Describe the pathophysiological connections between narcolepsy and increased cardiometabolic risk
- Explain the rationale and evidence behind the increased risk for major adverse cardiovascular events with commonly used narcolepsy agents
- Summarize recent updates with new and emerging narcolepsy treatments
- Select individualized treatment plans for narcolepsy patients with or are at increased cardiovascular risk
Virend K. Somers, MD, PhD
Professor of Medicine, Mayo Clinic
Dr. Somers discloses the following:
Consultant, Advisor, Speaker: Jazz, Huxley, Westper, ResMed, Respicardia, Bayer, Lilly, Scientific Advisory Board Sleep Number
Phyllis C. Zee, MD, PhD
Professor, Northwestern University Feinberg School of Medicine
Dr. Zee discloses the following:
Consultant, Advisor, Speaker: Eisai, Jazz, Sanofi-Aventis, Merck, CVS Caremark, KemPharm, Harmony Bioscience, Takeda
Other: Pfizer, Vanda
Individual publicly traded stocks and stock options: Teva
Richard K. Bogan, MD, FCCP, FAASM
Owner, Bogan Sleep Consultants, LLC
Dr. Bogan discloses the following:
Shareholder: WaterMark Medical, Healthy Humming, LLC
Board of Directors: WaterMark Medical
Consultant to Jazz, Harmony Biosciences, Takeda, Avadel, Oventus
Industry funded research for Avadel, BresoTec, Idorsia, Suven, Jazz, Balance, Vanda, Merck, Eisai, Philips, Fresca, Takeda, Liva Nova, Roche, Sommetrics, NLS, Sanofi, Apnimed
Speakers Bureau for Jazz, Eisai, Harmony, Idorsia
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-060-H01-P Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 1.5 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period March 1, 2023 through March 1, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.50 ABIM MOC and AMA PRA Category 1 Credit™
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.